The McKinsey Health Institute’s 2024 report on the global women’s health gap documented what researchers and advocates have known for decades: women spend a disproportionate share of their lives in poor health compared to men, and the conditions responsible for that gap are underfunded, underresearched, and poorly understood. The report estimated an annual economic cost exceeding $1 trillion. It called for a reorientation of research, clinical practice, and policy.
The report was widely cited. The institutional response has been modest.
What the Gap Actually Means
The global women’s health gap is not simply that women have worse health outcomes than men in every category. The picture is more specific and more damning: women live longer than men but spend more years of their lives sick or in pain. The conditions responsible for this gap — musculoskeletal disease, autoimmune conditions, mental health disorders, reproductive and gynecological conditions, and neurological conditions — are disproportionately female in prevalence and disproportionately underfunded in research.
The SWHR 2025 report calling for inclusive research, policies, and leadership to close the global women’s health gap identified three levers: more representative research that includes women and diverse populations, policy frameworks that address the conditions most responsible for female disease burden, and leadership — in research institutions, regulatory agencies, and health systems — that is itself more reflective of the population it serves.
The Research Investment Imbalance
The gap between women’s disease burden and research investment is not subtle. Conditions that disproportionately affect women receive systematically less NIH funding per disability-adjusted life year than conditions with more gender-balanced or male-skewed prevalence. This is not a recent development. It is a structural feature of how research priorities are set — through processes that have historically been led by and for men.
Correcting this requires explicit commitments: funding floors for underfunded conditions, enrollment requirements for underrepresented populations, and career pathways for researchers working in women’s health that do not treat the field as a niche.
What the U.S. Can Do
The United States has specific levers that other countries lack: the NIH, the largest biomedical research funder in the world; the FDA, whose drug approval processes shape global standards; and SWHR and allied organizations, which have decades of documented evidence of what happens when these institutions prioritize — or deprioritize — women’s health.
Awareness of the global women’s health gap is no longer the constraint. The constraint is action — and the political will to treat a $1 trillion problem as the emergency it is.
